Polar organic compounds found in industrial process waters, particularly those originating from biodegraded petroleum residues, include ‘naphthenic acids’ (NA).
Simulations Plus Announces Success in COX-2/COX-1 Drug Design Project
Three of Four Molecules Hit Both Targets
Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects
Accumulating evidence indicates that selective antagonism of kappa opioid receptors may provide therapeutic benefit in the treatment of major depressive disorder, anxiety disorders, and substance use disorders.
QbD and Biopharmaceutics – Use of Absorption Modeling
An informative online webinar that discusses the application of absorption modeling as a biopharmaceutics risk assessment tool to facilitate Quality by Design (QbD) arguments during formulation development.
Simulations Plus Reports Preliminary Revenues for Second Fiscal Quarter FY2014
Large Renewal Order Moves to Third Quarter, Still Posts Third Highest Quarterly Revenue
Simulations Plus Signs Research Collaboration Agreement with FDA
Company to Work with FDA on Mechanistic IVIVC Modeling
Semi-mechanistic modelling of the analgesic effect of gabapentin in the formalin-induced rat model of experimental pain
The formalin-induced rat model of nociception involves moderate continuous pain. Formalin-induced pain results in a typical repetitive flinching behaviour, which displays a biphasic pattern characterised by peaks of pain.
Imidazole aldoximes effective in assisting butyrylcholinesterase catalysis of organophosphate detoxification
Intoxication by organophosphate (OP) nerve agents and pesticides should be addressed by efficient, quickly deployable countermeasures such as antidotes reactivating acetylcholinesterase or scavenging the parent OP.
Neuroprotective Potential of Peroxisome Proliferator Activated Receptor-a Agonist in Cognitive Impairment in Parkinson’s Disease: Behavioral, Biochemical, and PBPK Profile
Parkinson’s disease (PD) is a common neurodegenerative disorder affecting 1% of the population by the age of 65 years and 4-5% of the population by the age of 85 years.
A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial
Entolimod (CBLB502) is a Toll-like receptor 5 agonist in development as a single-dose countermeasure against total body irradiation.
Simulations Plus Announces Quarterly Cash Dividend
Cash dividend declared of $0.05 per share
Differential effects of methoxy group on the interaction of curcuminoids with two major ligand binding sites of human serum albumin
Curcuminoids are a group of compounds with a similar chemical backbone structure but containing different numbers of methoxy groups that have therapeutic potential due to...
Use of Preclinical Dog Studies and Absorption Modeling to Facilitate Late Stage Formulation Bridging for a BCS II Drug Candidate
Formulation changes are common during drug development either due to clinical or manufacturing considerations. These changes especially at later stages of drug development oftentimes raise questions...
ADMET Predictor™ 7.0 Release
Learn about all the new features in ADMET Predictor 7.0 and how they can help you.
Simulations Plus Sets Date for 1st Quarter 2014 Earnings Release and Conference Call
Conference Call to be on Thursday, January 9, at 4:15 PM ET
Simulations Plus Reports First-Quarter FY2014 Financial Results
Net sales increase 15.3% to first quarter record $2.641 million; Earnings up 16.7%
Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium
Pyrvinium pamoate (PP) is a potent noncompetitive inhibitor of the androgen receptor (AR). Using a novel method of target identification, we demonstrate that AR is a...
Evaluation and Optimisation of Current Milrinone Prescribing for the Treatment and Prevention of Low Cardiac Output Syndrome in Paediatric Patients After Open Heart Surgery Using a Physiology-Based Pharmacokinetic Drug-Disease Model
Milrinone is the drug of choice for the treatment and prevention of low cardiac output syndrome (LCOS) in paediatric patients after open heart surgery across Europe.
Population Pharmacokinetic Evaluation of Eslicarbazepine Acetate for Adjunctive Therapy in Refractory Partial Onset Seizures
Eslicarbazepine acetate (ESL), a once-daily antiepileptic drug (AED), is converted to eslicarbazepine, the primary active metabolite of ESL, after oral administration. The population pharmacokinetics (PK)…